Table 2 Toxicity profile and safety summary
Feature | Frequency |
|---|---|
Number of cycles received, mean (range) | 4 (2–6) |
All–grade AEs, any cause, n (%) | 5 (100%) |
Treatment–related AE | 5 (100%) |
Immune–related AE | 3 (60%) |
Grade 3 AEs, any cause, n (%) | 2 (40%) |
Treatment–related grade 3 AEs | 2 (40%) |
Treatment–related AEs leading to withdrawal from treatment | 1 (20%) |
AEs leading to dose modification or interruption, n (%) | 3 (60%) |
AEs leading to death, n (%) | 0 (0%) |